Quick Takeaways:
- KVP SafePath has entered into a strategic agreement with Bioguard Corporation to accelerate development and regulatory approval of veterinary diagnostic assays in North America. The collaboration will leverage Bioguard’s reagent library and IP to support both USDA-licensed and USDA-exempt assays
- As part of the deal, KVP SafePath plans to pursue USDA licensing for Canine and Feline 4DX and 3DX diagnostic panels, targeting a segment valued at >$500M annually in North America. The partnership is expected to shorten development timelines while strengthening KVP’s diagnostic portfolio and commercialization capabilities
- Building on an existing relationship, the agreement also enables Bioguard to access the North American veterinary diagnostics market via KVP SafePath’s distribution network. By combining Bioguard’s scientific expertise with KVP’s regulatory and commercial strengths, the companies aim to expand innovative, reliable diagnostic solutions for veterinary professionals
Why It Matters?
The Bioguard agreement deepens KVP SafePath’s diagnostics pipeline with access to a broad reagent/IP library and a faster path to USDA‑licensed 4DX/3DX panels, positioning the company to enter a >$500 million North American segment with a more complete test menu.
For Bioguard, the partnership provides a de‑risked route into the world’s largest veterinary diagnostics market by leveraging KVP’s regulatory, manufacturing, and distribution strengths, turning a reagent‑IP business into a North America‑facing commercial diagnostics player.
Source: PRnewswire
